<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01973569</url>
  </required_header>
  <id_info>
    <org_study_id>AMG162-D-J301</org_study_id>
    <nct_id>NCT01973569</nct_id>
  </id_info>
  <brief_title>AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Patients With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment</brief_title>
  <acronym>DESIRABLE</acronym>
  <official_title>A Confirmatory Study of AMG 162 (Denosumab) in Patients With Rheumatoid Arthritis on DMARDs Treatment (Phase III)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the inhibitory effect of progression, compared with placebo, in joint destruction
      by AMG 162 administered subcutaneously to rheumatoid arthritis patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the inhibitory effect of progression, compared with placebo, in joint destruction
      by AMG 162 administered subcutaneously at a dose of 60 mg every 6 months or every 3 months
      for 12 months to rheumatoid arthritis patients
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2013</start_date>
  <completion_date type="Actual">July 3, 2017</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Total Sharp Score (TSS) at month 12</measure>
    <time_frame>baseline to month 12</time_frame>
    <description>Change from baseline in Total Sharp Score (TSS) from baseline to month 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change form baseline in TSS at month 6</measure>
    <time_frame>baseline to month 6</time_frame>
    <description>Change from baseline in Total Sharp Score (TSS) from baseline to month 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change form baseline in Erosion Score at month 6</measure>
    <time_frame>baseline to month 6</time_frame>
    <description>Change from baseline in Erosion Score from baseline to month 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change form baseline in Joint Space Narrowing at month 6</measure>
    <time_frame>baseline to month 6</time_frame>
    <description>Change from baseline in Joint Space Narrowing from baseline to month 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change form baseline in Erosion Score at month 12</measure>
    <time_frame>baseline to month 12</time_frame>
    <description>Change from baseline in Erosion Score from baseline to month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change form baseline in Joint Space Narrowing at month 12</measure>
    <time_frame>baseline to month 12</time_frame>
    <description>Change from baseline in Joint Space Narrowing from baseline to month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percent change from baseline in Bone Mineral Density (BMD) at month 12</measure>
    <time_frame>baseline to month 12</time_frame>
    <description>percent change from baseline in Bone Mineral Density (BMD) at month 12</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">667</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Denosumab 6 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>denosumab administered subcutaneously every 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Denosumab 3 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>denosumab administered subcutaneously every 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo administered subcutaneously to match denosumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>denosumab</intervention_name>
    <description>denosumab administered subcutaneously</description>
    <arm_group_label>Denosumab 6 months</arm_group_label>
    <arm_group_label>Denosumab 3 months</arm_group_label>
    <other_name>AMG 162</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo administered subcutaneously to match denosumab</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with rheumatoid arthritis according to the American College of Rheumatology
             (ACR) criteria for rheumatoid arthritis classification (1987 revision) or the 2010
             ACR-EULAR (The European League Against Rheumatism) classification criteria for
             rheumatoid arthritis

        Exclusion Criteria:

          -  Functional class IV according by the ACR revised classification (1991)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tsutomu Takeuchi, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Division of Rheumatology Department of Internal Medicine, Keio University</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <zip>162-0054</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2013</study_first_submitted>
  <study_first_submitted_qc>October 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2013</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Denosumab</keyword>
  <keyword>RANKL</keyword>
  <keyword>RANK</keyword>
  <keyword>AMG 162</keyword>
  <keyword>joint damage</keyword>
  <keyword>Developmental Phase III</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
    <mesh_term>Antirheumatic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

